Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA, CMS Joint Guidance On Studies Using Cancer Biomarkers Sought In Bill

Executive Summary

FDA and CMS are directed to jointly develop guidelines on clinical studies relating to cancer care and treatment biomarkers in legislation (S. 717) introduced by Sens. Ted Kennedy, D-Mass., and Kay Bailey Hutchinson, R-Texas, on March 26

You may also be interested in...

Predictive Biomarkers Can Be Supported By Two Well-Conducted Retrospective Studies - FDA Advisors

Advisory committee considers biomarker validation in context of KRAS biomarker for the cancer agents Vectibix and Erbitux

Tri-Agency Oncology Biomarker Initiative Commences With PET Scan Study

Oncology biomarker qualification efforts jointly tackled by FDA, the National Cancer Institute and CMS will encompass prospective studies and ongoing clinical trials

ICER Partnering With Aetion To Scale Up Use Of RWE In Value Assessments

Aetion is also working with the US Food and Drug Administration and a number of biopharma companies on projects involving use of real-world evidence.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts